Compare Cytokinetics Inc (CYTK) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Cytokinetics Inc trades at $76.34 (market cap $10.63B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.18. The key difference: Cytokinetics Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | LQD | |
|---|---|---|
Market Cap | $10.63B | — |
Sector | Technology | — |
52-Week High | $87.26 | $112.91 |
52-Week Low | $34.31 | $105.96 |
Enterprise Value | $10.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
LQD, the iShares iBoxx $ Investment Grade Corporate Bond ETF, trades at $106.335, up 0.35% today, while technical indicators signal a bearish trend with moving averages and key oscillators in sell or neutral territory. The ETF has declared several dividends for 2026, with payments scheduled through August, reflecting its income-focused strategy amid fluctuating bond markets driven by inflation fears and geopolitical tensions.
The outlook for LQD is cautious due to bearish technicals and macroeconomic pressures like rising oil prices and potential Fed rate hikes, which could pressure corporate bond yields. Investors may find value in its investment-grade corporate debt exposure for diversification, but must monitor interest rate volatility and economic data closely for risks to fixed income returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
